2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - 252-254
Technology and Procedures, Imaging, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Non-Biological Therapies, Biological Processes, Microbiome, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Measurable Residual Disease, Research, Clinical Research, Clinical Trials, Health Outcomes Research, Study Population, Human, Adult, Young Adult
PAPER

743 Hematopoietic stem cell transplant to cure sickle cell disease at an older age increases the brain age gap

Heather Roberts, MS, Amy Mirro, MEng2, April Ratliff, PhD3, Yonca Cam, PhD4, Emily Shen5, Nardeen Ayad, MBBS, MSc6, Andria Ford, MD, MSCI7, Kristin Guilliams, MD, MSCI8, Shalini Shenoy, MD9, Melanie Fields, MD, MSCI10
1 Washington University, St. Louis, Missouri, United States
2 Washington University, St. Louis, Missouri, United States
3 Washington University, St. Louis, Missouri, United States
4 Washington University, St. Louis, Missouri, United States
5 Washington University, St. Louis, Missouri, United States
6 Washington University, St. Louis, Missouri, United States
7 Washington University, St. Louis, Missouri, United States
8 Washington University, St. Louis, Missouri, United States
9 Washington University, St. Louis, Missouri, United States
10 Washington University, St. Louis, Missouri, United States

People living with sickle cell disease (SCD) are at risk for neurologic complications including stroke and cognitive dysfunction. Curative hematopoietic stem cell transplant (HSCT) in SCD addresses these complications by normalizing cerebral hemodynamics, stabilizing cognitive decline and reducing the rate of new infarction. However, HSCT also carries significant acute risks including infection, graft versus host disease (GVHD), posterior reversible encephalopathy, and others. Previous work has shown that risks associated with HSCT are age dependent, with younger age at transplant associated with more favorable outcomes. DeepBrainNet, a machine learning tool, predicts brain age from structural T1 MR images, enabling computation of brain age gap (BAG, predicted brain age – chronological age). We have shown that BAG is regionally reduced in brain regions at greatest risk for stroke in children with SCD, even in the absence of infarction, suggesting BAG can be used as a general metric of brain health.  We calculated BAG in children with SCD before and after HSCT to define the acute neurological impact of HSCT, beyond overt neurological complications such as stroke or seizure, and whether age at HSCT (<10 versus ≥10 years (yr)) impacted the relationship between HSCT and BAG.

Brain MRIs from 46 children with SCD that received HSCT at St. Louis Children’s Hospital before 2025 were collected. Participants were excluded for graft loss (N=3), non-SCD related neurologic disease (N=1) and lack of brain MRI before and after HSCT (N=13).  DeepBrainNet predicted brain age, permitting calculation of BAG, for each MRI as previously described. Linear mixed-effects models with participant-specific random intercepts were used to account for repeated measures. Sequential models evaluated 1) whether HSCT altered the relationship between chronological age and BAG, 2) whether this effect differed according to age at HSCT (<10 versus ≥10 yrs), and 3) post-HSCT BAG recovery trajectories.

Twenty-nine participants with SCD (22 HbSS, 2 HbSβ0, 2 HbSC, 3HbSβ+) with a median age of 11.2 [IQR 6.0, 16.9] yrs at HSCT met inclusion/exclusion criteria for analyses. Matched sibling (N=11, 37.9%), unrelated (N=12, 41.4%) and haploidentical (N=6, 20.7%) donors were utilized for HSCT. Eighteen participants (62.1%) experienced stroke (silent or overt) before HSCT. Stroke prevalence was not different between age cohorts (<10 yrs: 6/12, ≥10 yrs: 12/17, p=0.438). A total of 143 MRIs from 29 participants were included (70 pre-HSCT MRIs,73 post-HSCT MRIs). A median of 2 MRIs was obtained post-HSCT for a follow-up of 2.0 [IQR 1.3, 2.4] yrs in participants transplanted at <10 yrs of age versus 3 MRIs (p=0.292) for a follow-up of 2.0 [IQR 1.0, 6.1] yrs (p=0.452) in those transplanted at ≥10 yrs of age. BAG trajectories differed significantly before and after HSCT. BAG was estimated to be 3.0 yrs higher post-HSCT, and the relationship between chronological age and BAG became significantly steeper post-HSCT (interaction β=0.49 BAG-yrs/yr, p=0.011). Chronological age at time of MRI was not independently associated with BAG (p=0.79), nor did the age groups (<10 versus ≥10 yrs at HSCT) differ significantly in BAG prior to HSCT (p=0.62).The effect of HSCT on BAG was modified by age at HSCT (interaction β=−6.42 yrs, p=0.0045) with a 6.0 yr increase in BAG in participants undergoing HSCT at ≥10 yrs of age, whereas participants transplanted before age 10 yrs demonstrated little change in BAG following HSCT (approximately −0.40 yrs). Exploratory modeling of post-HSCT trajectories were consistent with a gradual decline in BAG towards the pre-HSCT level over approximately two yrs, although substantial between-subject variability limited formal inference regarding recovery rates.

These results suggest that older age at HSCT may be associated with a greater increase in BAG, the difference between predicted brain age and chronological age. Future investigation is required to determine the impact of clinical complications, such as acute infection or GVHD, on the impact of HSCT on BAG.  While an increase in BAG may not directly equate to brain aging, these data suggest the acute neurologic impact of HSCT may differ depending on the timing of HSCT and that HSCT potentially impacts the brain even if overt neurologic complications are not experienced. Advanced neuroimaging biomarkers can potentially be utilized to determine the optimal timing for curative and transformative therapies.

Heather Roberts, MS: No relevant conflicts of interest to declare.